Roche Strikes Up to $15 Billion Cancer Drug Deal With China's Hansoh
The Swiss pharmaceutical giant has agreed to a massive licensing agreement with Chinese firm Hansoh Pharmaceutical Group for antibody-drug conjugates.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
First reported by Quartz, 43 min ahead of the next publisher · who breaks stories first
This story has stopped developing; this page is its permanent record. More from that day
The story so far
4 publishers have covered this in 8 articles since 19 Oct 2026. Quartz published first, on 19 October at 12:40 UTC; STAT followed 44 min later. The most recent article, from MedPageToday.com - medical news for physicians, appeared on 23 October at 21:13 UTC.
Outlets reporting it: Bloomberg.com (major outlet), Quartz, STAT, MedPageToday.com - medical news for physicians.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
How it unfolded
Every source in the order it published.
- QuartzRoche struck a cancer drug licensing deal with China's Hansoh that could exceed $15 billion
- QuartzRoche hat einen Lizenzvertrag für Krebsmedikamente mit dem chinesischen Unternehmen Hansoh abgeschlossen, der mehr als 15 Milliarden Dollar wert sein könnte.
- STATSTAT+: Pharmalittle: We’re reading about Roche investments in Germany, a Gilead bowel disease drug, and more
- STATSTAT+: Roche continues to look to China for new drugs
- Bloomberg.comRoche Sales Beat Estimates, Helped by Older Blockbuster Xolair
- STATSTAT+: Pharmalittle: We’re reading about a U.S. rule on Chinese deals, Belgium refusing Mounjaro coverage, and more
- STATSTAT+: Most cancer drugs approved by European regulators lack a high clinical benefit, analysis finds
- MedPageToday.com - medical news for physiciansChinese Drug Shows Benefit in HER2-Low Breast Cancer
Sources
Every article we clustered into this story. Headlines link to the publisher.
- Roche Sales Beat Estimates, Helped by Older Blockbuster Xolair Bloomberg.com ·
- Chinese Drug Shows Benefit in HER2-Low Breast Cancer MedPageToday.com - medical news for physicians
- STAT+: Most cancer drugs approved by European regulators lack a high clinical benefit, analysis finds STAT
- STAT+: Pharmalittle: We’re reading about a U.S. rule on Chinese deals, Belgium refusing Mounjaro coverage, and more STAT
- STAT+: Roche continues to look to China for new drugs STAT
- STAT+: Pharmalittle: We’re reading about Roche investments in Germany, a Gilead bowel disease drug, and more STAT
- Roche struck a cancer drug licensing deal with China's Hansoh that could exceed $15 billion Quartz
- Roche hat einen Lizenzvertrag für Krebsmedikamente mit dem chinesischen Unternehmen Hansoh abgeschlossen, der mehr als 15 Milliarden Dollar wert sein könnte. Quartz
In this story
- Roche
- Hansoh Pharmaceutical Group
- China